|
Genflow Biosciences PLC on Friday reported strong data from a proof-of-concept clinical trial of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The London-based biotechnology firm said the gene therapy has now been administered for the second time in its ongoing trial involved 28 beagles aged 10 years and older. In March, recipients received three different modalities of the therapy, with no ill or adverse effects observed, Genflow said. The repeat administration showed an ‘excellent safety and tolerability profile’, the company said. The dogs are currently in a follow-up period which is expected to conclude in January. Genflow said the results show the robustness of its gene therapy platform and its potential applicability beyond human health. The SIRT6 gene plays a key role in DNA repair, metabolic regulation and resistance to age-related decline. Genflow added that it aims to introduce longevity-based treatments into the animal health market, to target improved healthspan, vitality and lifespan in both companion and livestock animals. ‘We’re very encouraged by the continued safety validation of our SIRT6 therapy and by the strong engagement we’re seeing from established players in the animal health industry,’ said Chief Executive Officer Eric Leire. ‘The animal health market represents an attractive near-term commercial opportunity for Genflow, complementing our core human longevity programs while showcasing the broader potential of our gene therapy platform.’ Genflow said it will continue to advance its animal health initiative towards the next stage of clinical evaluation. Shares in Genflow Biosciences were up 4.8% at 2.20 pence in London on Friday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
